Truist Securities Downgrades ANI Pharmaceuticals to Hold, Lowers Price Target to $60
Portfolio Pulse from Benzinga Newsdesk
Truist Securities has downgraded ANI Pharmaceuticals from Buy to Hold and reduced its price target from $80 to $60.
September 11, 2024 | 10:47 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Truist Securities has downgraded ANI Pharmaceuticals from Buy to Hold, reducing the price target from $80 to $60, indicating a less optimistic outlook.
The downgrade from Buy to Hold suggests that the analyst sees less potential for upside in ANI Pharmaceuticals' stock. The reduction in the price target from $80 to $60 further indicates a more cautious outlook on the company's future performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100